公开(公告)号：HUE047537T2

公开(公告)日：2020-05-28

申请号：HUE16807756

申请日：2016-06-07

Applicant: DAE WOONG PHARMA

Inventor： PARK JOON SEOK ,  YOON YOUN JUNG ,  CHO MIN JAE ,  LEE HO BIN ,  YOO JA KYUNG ,  LEE BONG YONG

IPC: A61P35/00

公开(公告)号：MY174343A

公开(公告)日：2020-04-09

申请号：MYPI2016704579

申请日：2015-06-23

Applicant: DAE WOONG PHARMA

Inventor： PARK JOON SEOK ,  YOON YOUN JUNG ,  CHO MIN JAE ,  LEE HO BIN ,  YOO JA KYUNG ,  LEE BONG YONG

Abstract: The present invention relates to a compound represented by chemical formula 1, which can be used for the prevention and treatment of diseases caused by abnormality in a prolyl-tRNA synthetase (PRS) activity, or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition comprising the same. The Most Illustrative Drawings: Figure 1.

公开(公告)号：BR112019017795A2

公开(公告)日：2020-03-31

申请号：BR112019017795

申请日：2018-02-27

Applicant: CG BIO CO LTD ,  DAE WOONG PHARMA ,  DNCOMPANY

Inventor： HAK SU JANG ,  HYE YOUNG JUNG ,  JI SUN LEE ,  JUNG EUN CHOO ,  SU HYUN JUNG

IPC: A61L27/20 ,  A61L27/58

Abstract: a presente invenção se refere a uma composição para injeção dérmica que inclui dois ou mais tipos de partículas de ácido hialurônico reticulado com diferentes diâmetros de partículas e ácido hialurônico não reticulado. a composição para injeção dérmica de acordo com a presente invenção satisfaz as condições de viscosidade, força de extrusão e viscoelasticidade para injeção dérmica, e um desvio da força de extrusão é baixo para que o usuário não sinta fadiga quando a composição é injetada na região dérmica do mesmo. além disso, a composição é excelente em viscoelasticidade e capacidade de restauração de tecidos, é mantida por um longo período de tempo, permite recuperação rápida porque um grau de inchaço inicial é baixo e também é excelente em segurança e estabilidade no corpo.

公开(公告)号：CA3110830A1

公开(公告)日：2020-03-26

申请号：CA3110830

申请日：2019-09-19

Applicant: DAE WOONG PHARMA

Inventor： SHIN JEONG TAEK ,  SON JEONG HYUN ,  EOM DEOK KI

IPC: C07D207/48 ,  A61K31/40 ,  A61P1/00

Abstract: The present invention relates to a method for producing a 4-methoxy pyrrole derivative. According to one embodiment, the present invention can provide a useful advantage of industrial mass production of a 4-methoxy pyrrole derivative, as the process efficiency and yield are improved and the use of hazardous reagents and environmental pollution reagents is excluded.

公开(公告)号：BR112019015428A2

公开(公告)日：2020-03-24

申请号：BR112019015428

申请日：2018-03-19

Applicant: DAE WOONG PHARMA

Inventor： IN WOO KIM ,  JA KYUNG YOO ,  JI DUCK KIM ,  JUN HEE LEE ,  SUN AH JUN

IPC: A61K31/53 ,  C07D487/04

Abstract: trata-se de um composto representado pela fórmula química 1 definido no presente relatório descritivo ou um sal farmaceuticamente aceitável do mesmo. o composto de acordo com a presente invenção pode ser usado de maneira útil para a prevenção ou tratamento de doenças que são associadas às ações inibitórias de quinase.

公开(公告)号：HUE046208T2

公开(公告)日：2020-02-28

申请号：HUE16185155

申请日：2016-08-22

Applicant: DAE SAN ELECTRONICS CO LTD

Inventor： MA SANG YOUNG ,  YEO UN EOG

IPC: H01M2/30 ,  C25D5/02 ,  C25D7/00 ,  H01M2/20

公开(公告)号：IL257928A

公开(公告)日：2020-02-27

申请号：IL25792818

申请日：2018-03-06

Applicant: HANMI SCIENCE CO LTD ,  SUNG YOUB JUNG ,  YOUNG EUN WOO ,  SE CHANG KWON ,  DAE JIN KIM ,  SUNG HEE PARK ,  IN YOUNG CHOI

Inventor： SUNG YOUB JUNG ,  YOUNG EUN WOO ,  SE CHANG KWON ,  DAE JIN KIM ,  SUNG HEE PARK ,  IN YOUNG CHOI

IPC: A61K38/26 ,  A61K38/00 ,  A61K45/06 ,  A61K47/60 ,  A61K47/68 ,  C07K14/575

Abstract: The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

公开(公告)号：PT3303320T

公开(公告)日：2020-02-03

申请号：PT16807756

申请日：2016-06-07

Applicant: DAE WOONG PHARMA

IPC: C07D401/06 ,  A61K31/4184 ,  A61K31/4439 ,  C07D235/04

公开(公告)号：IL249246A

公开(公告)日：2020-01-30

申请号：IL24924616

申请日：2016-11-27

Applicant: HANMI PHARM IND CO LTD ,  KIM JUNG KUK ,  KIM DAE JIN ,  HEO YONG HO ,  CHOI IN YOUNG ,  JUNG SUNG YOUB ,  KWON SE CHANG

Inventor： KIM JUNG KUK ,  KIM DAE JIN ,  HEO YONG HO ,  CHOI IN YOUNG ,  JUNG SUNG YOUB ,  KWON SE CHANG

IPC: A61K38/28 ,  A61K38/26 ,  A61K47/30 ,  A61K47/50 ,  A61P3/10 ,  C07K14/605 ,  C07K14/62

Abstract: The present invention relates to a composition for the prevention or treatment of diabetes including a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a method for treating diabetes. More specifically, combination administration of the long-acting analogue conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain due to administration of insulin, and vomiting and nausea due to administration of the insulinotropic peptide, and also reduces the required doses of insulin, thereby remarkably improving drug compliance. In addition, the present invention relates to administering a pharmaceutical composition for reducing side effects of pancreatic beta cells in diabetic patients, including a long-acting insulin analogue conjugate and a long-acting insulinotropic peptide analogue conjugate, and to a method for reducing side effects of pancreatic beta cells in diabetic patients, including the step of administering the composition. Specifically, the present invention is characterized in reducing side effects such as abnormality in the function of pancreatic beta cells associated with the development of diabetes, reduction in the pancreatic beta cell mass, lipotoxicity, or glucotoxicity.

公开(公告)号：DOP2019000291A

公开(公告)日：2019-12-15

申请号：DO2019000291

申请日：2019-11-14

Applicant: DAE WOONG PHARMA

Inventor： JEONG-TAEK SHIN ,  SEUNG CHUL LEE ,  JEONG HYUN SON

IPC: A61K31/4015 ,  C07D207/36

Abstract: La presente invención se refiere a un método para preparar productos intermedios de derivados de 4-metoxipirrol. El método de preparación según la presente invención tiene las ventajas de que el coste de producción puede reducirse usando materiales de partida económicos, no se requiere una elevada temperatura de reacción en su totalidad, se usan reactivos económicos y no explosivos en lugar de (trimetilsilil)diazometano, y puede prepararse además un producto intermedio de derivados de 4-metoxipirrol en su totalidad a un alto rendimiento.